Trial Profile
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs BMS 986207 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Apr 2024 Status changed from active, no longer recruiting to completed.
- 09 May 2023 Planned End Date changed from 19 Aug 2024 to 18 Feb 2025.
- 09 May 2023 Planned primary completion date changed from 19 Aug 2024 to 19 Mar 2024.